Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon GloboCare Corp. reports developments across precision diagnostic consumer products, generative AI publishing and software, and related intellectual property. The company markets the KetoAir breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and it has described plans to extend breathalyzer technology into additional diagnostic uses.
Recurring company updates also cover Avalon Quantum AI LLC, the Catch-Up generative and agentic AI video platform, provisional patent filings for automated commentary systems, and technology collaborations supporting AI media infrastructure. Avalon news also includes capital-structure actions such as private placements, warrant issuances, debenture conversions, shareholder approvals, and Nasdaq compliance matters.
Avalon Quantum AI (NASDAQ: ALBT) announced a collaboration with Amazon Web Services and Caylent to support Phase 2 development of its Catch-Up agentic AI video platform on April 21, 2026.
Phase 2 aims to convert the platform from a manually configured tool into a fully autonomous agentic AI video system to help nontechnical creators generate personalized social media video content and scale the SaaS offering.
Avalon (NASDAQ: ALBT) announced on March 31, 2026 that its subsidiary Avalon Quantum AI selected Caylent, an AWS Premier Tier partner, to support phase 2 development of the Catch-Up SaaS platform.
The collaboration aims to evolve Catch-Up from a manually configured AI video production system into a fully autonomous, agentic AI video platform for creators and enterprises.
Avalon GloboCare (NASDAQ: ALBT) closed a private placement priced at-the-market on Feb 27, 2026, selling 6,372,550 shares (or pre-funded warrants) with associated warrants at $0.51 per share, raising approximately $3.25 million of gross proceeds.
The financing includes Series A-1 and A-2 warrants to purchase up to 6,372,550 shares each, exercisable at $0.51 if and when stockholder approval is effective; A-1 expire five years and A-2 expire 18 months from stockholder approval. The company may receive up to ~$6.5 million more if warrants are fully exercised. Net proceeds are intended for debt repayment and working capital.
Avalon GloboCare (NASDAQ: ALBT) entered definitive agreements for a private placement to sell 6,372,550 shares (or pre-funded warrants) and associated Series A-1 and A-2 warrants at $0.51 per share.
The offering is expected to close on or about February 27, 2026, raising approximately $3.25 million in gross proceeds upfront and up to an additional $6.5 million if warrants are fully exercised. Net proceeds will be used to repay certain debt and for working capital.
Avalon GloboCare (NASDAQ: ALBT) was accepted into the AMD AI Developer Program on Feb. 26, 2026, giving its AI subsidiary AQAI access to AMD Developer Cloud credits, tools, training, and community resources.
Avalon plans to use AMD Instinct accelerators and EPYC processors to speed model training, inference, and scalability for automated evidence-constrained video generation, AI-assisted drafting, compliance tooling, and workflow automation.
Avalon GloboCare (NASDAQ: ALBT) subsidiary Avalon Quantum AI filed a U.S. provisional patent application (No. 63/961,892) on Feb 18, 2026 for an AI system that generates multiple audience-adaptive commentary video variants from a shared evidence framework while preserving factual integrity.
The platform is designed to tailor tone, pacing, and presentation by audience profile, collect performance data to refine strategies, and adapt outputs for short- and long-form formats, regional/regulatory requirements, and brand-safe distribution. Potential applications cited include personalized financial commentary, sports recaps, and marketing content.
Avalon GloboCare (NASDAQ: ALBT) announced conversion of the majority of its outstanding debentures from a June 2024 convertible note financing, strengthening its balance sheet and reducing overhang.
The financing had an aggregate principal of $2.8 million; $288,000 was repaid in cash and $2.6 million was converted into common stock, which the company believes has largely been sold. Avalon said the conversion improves financial transparency and supports its return to Nasdaq minimum stockholders' equity compliance while enabling progress on diagnostic and AI initiatives.
Avalon GloboCare (NASDAQ: ALBT) said subsidiary Avalon Quantum AI filed a U.S. provisional patent application (No. 63/961,889) on Jan 16, 2026 for “Systems and Methods for Evidence-Constrained, Audience-Adaptive Generation of Automated Commentary Videos.”
The filing describes an AI architecture that enforces evidence-linked generation, builds structured evidence graphs, detects source contradictions, applies uncertainty handling, and embeds traceability and audit metadata into video outputs to support editorial review, compliance validation, and accountability.
Avalon GloboCare (NASDAQ: ALBT) announced renewal of the U.S. FDA establishment registration for the KetoAir™ handheld breathalyzer (registration no. 3026284320). KetoAir measures breath acetone concentration (BrAce) using nanosensor technology to provide non-invasive metabolic and ketosis insights for users on ketogenic programs. Avalon plans a combined B2B and B2C launch for KetoAir via Catch-Up™, its generative AI short-form video SaaS, operated by Avalon Quantum AI, LLC. Marketing through Catch-Up™ is planned to begin in the second quarter of 2026 to support distribution, engagement, and adoption across enterprise and consumer channels.
Avalon GloboCare (NASDAQ: ALBT) announced it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement under Rule 5550(b) and is now in compliance with all continued listing standards. The previously scheduled Nasdaq Hearings Panel session was cancelled and Avalon’s common stock will remain listed and traded on Nasdaq.
The company said restoring compliance supports its ability to pursue growth initiatives, including launching marketing for a generative AI video platform and expanding precision diagnostics and strategic assets.